Contact Support: 512-708-4678


New Course Alerts and CME News

BLOCK HIV/HCV Birmingham
Intergritas Communications

Birmingham, AL
Oct 18, 2019

Approximately 25% of all individuals infected with HIV are coinfected with HCV.1 Of critical significance, HIV increases the rate of progression of HCV-related hepatic fibrosis, and HCV is associated with a 3-fold increase in HIV antiretroviral therapy (ART)–induced liver toxicity.2 Further, these synergistic diseases often occur within adverse socioeconomic conditions that significantly increase the vulnerability and decrease the overall health status of at-risk populations.3Whereas HIV infection is now effectively manageable, chronic HCV infection is curable. Yet, despite new, highly effective direct-acting antiviral (DAA) treatment regimens for HCV, their broad-scale use and associated therapeutic successes remain stymied by barriers at the patient, clinician, health care system, and jurisdictional levels.4 The BLOCK HIV/HCV initiative will provide community-based infectious disease specialists and other HIV treaters with foundational information and practical resources needed to prepare local stakeholders—both clinical and nonclinical—to collaborate in efforts to eliminate HCV within their communities.

  1. Centers for Disease Control and Prevention. HIV/AIDS and Viral Hepatitis.
    Accessed January 24, 2018.
  2. Sulkowski MS, Benhamou Y. Therapeutic issues in HIV/HCV-coinfected patients. J Viral Hepat. 2007;14(6):371-386.
  3. Singer M. Introduction to Syndemics: A Critical Systems Approach to Public and Community Health. San Francisco, CA: Jossey-Bass; 2009.
  4. National Viral Hepatitis Roundtable (NVHR). Hepatitis C: The State of Medicaid Access. October 23, 2017. Accessed January 24, 2018

After completing this activity, the partcipant should be better able to:

  • Describe epidemiologic trends in HCV monoinfection and HIV/HCV coinfection within at-risk populations, including men who have sex with men (MSM), people who inject drugs (PWID), and incarcerated individuals
  • Provide guideline-based treatment for HCV monoinfection and HIV/HCV coinfection
  • Identify patient, provider, and health care system barriers to effective management of HCV monoinfection and HIV/HCV coinfection
  • Implement strategies to overcome risk-cohort–specific challenges to the treatment of HCV
    monoinfection and HIV/HCV coinfection

This activity is intended for a multidisciplinary audience including community-based infectious disease specialists and other HIV treaters, gastroenterology/hepatology clinicians, mental health specialists, substance abuse specialists, correctional health care professionals, public policy/public health officials, hepatitis C virus (HCV) and HIV advocacy groups, payers, and clinical office staff who are engaged in the care of patients with HIV and/or HCV.

10 minutes    Welcome and Preactivity Polling

30 minutes    The Challenge of HCV Elimination

30 minutes    HCV Therapy: The State of the Union

20 minutes    Populations in Greatest Need—Men Who Have Sex With Men (MSM)

20 minutes    BREAK

30 minutes    Populations in Greatest Need—People Who Inject Drugs (PWID)

20 minutes    Other Real-World Circumstances

20 minutes    Success Stories

30 minutes    LUNCH

30 minutes    Addressing Region-Specific Barriers and Challenges to HCV                                                                 


10 minutes    Introduction to Small-Group Breakouts: Bringing Together 

                      Stakeholders and Creating a Collaborative Plan

30 minutes    Multidisciplinary Small Groups: Putting a Plan Into Action

60 minutes    Panel Discussion: The Call to Action & Beyond

20 minutes    Closing Statements & Postactivity Polling

There is no registration fee. 

Click here to register for this meeting. 


In support of improving patient care, this activity has been planned and implementedbythe Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the

American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.


The Postgraduate Institute for Medicine designates this live activity for a maximum of 6.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Postgraduate Institute for Medicine designates this continuing education activity for 6.5 contact hours (0.65 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - JA4008162-9999-19-748-L02-P)



Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.  Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service.


The maximum number of hours awarded for this Continuing Nursing Education activity is 6.5 contact hours.
Pharmacotherapy contact hours for Advanced Practice Registered Nurses to be determined.  

Social Worker and Case Manager credit will be applied for, but is not guaranteed at this time.


As a Jointly Accredited Organization, Postgraduate Institute for Medicine is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program.  Organizations, not individual courses, are approved under this program.  State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit.  Postgraduate Institute for Medicine maintains responsibility for this course.  Social workers completing this course receive 6.5 clinical continuing education credits.


This program has been submitted to The Commission for Case Manager Certification for approval to provide board certified case managers with 6.5 clock hours.


Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they may have as
related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. 
The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.


Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Nora Eldasher prior to the live event at